Current Illinois CancerCare Clinical Trials

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study (DiRECT)

Study Number: URCC 21038

Study Summary:
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.

Status: Open

Study Coordinator(s)
  • Navigator Courtney, 309-243-3660 cbrown@illinoiscancercare.com
  • Hannah S, 309-243-3603, hshearburn@illinoiscancercare.com
  • Kelsey, 309-243-3618 kfay@illinoiscancercare.com

Study Link

« Search Again